Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $889.01M
• Dividend Yield: N/A
• Average Volume (3M): 1.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: -78.55%
• EPS Growth: 7.74%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 139,125,030
• 10 Day Avg. Volume: 1,553,446
• 30 Day Avg. Volume: 1,518,806
• PEG Ratio: 0.12
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 13.48
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 22.82
• Enterprise Value/Gross Profit: -0.88
• Enterprise Value/Ebitda: -0.75
• 1Y Price Target: $17.67
• Price Target Upside: 176.53% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -3.48
• Revenue Forecast (FY): $6.42M

• Rating: 51 Neutral
• Price Target: $6.50 ▲(1.72% Upside)

Vir Biotechnology's overall stock score is primarily impacted by its poor financial performance, which is the most significant factor. Despite positive technical indicators suggesting short-term bullish momentum, the company's valuation remains unattractive due to negative earnings and no dividend yield. The earnings call provided some positive insights into clinical progress and a strong cash position, but these are overshadowed by ongoing financial challenges.

Positive Factors

Strong Cash Position

A strong cash position provides financial stability and flexibility, enabling continued investment in R&D and strategic initiatives without immediate funding pressures.

Progress in Clinical Programs

Timely progress in clinical trials enhances the potential for future regulatory approvals and commercialization, strengthening the company's pipeline and market position.

R&D Efficiency

Improved R&D efficiency through cost savings enhances the company's ability to allocate resources effectively, supporting long-term innovation and profitability.

Negative Factors

Negative Revenue Growth

Negative revenue growth and profitability issues can hinder sustainable business operations, limiting the company's ability to invest in future growth opportunities.

High R&D Expenses

High R&D expenses, while necessary for innovation, can strain financial resources and impact short-term profitability, requiring careful management to ensure long-term success.

Dependence on Future Data

Reliance on future clinical data introduces uncertainty, as any setbacks could delay product development and affect the company's growth trajectory and market expectations.

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through the development and commercialization of its therapeutic products. Key revenue streams include sales of approved products, licensing agreements, and collaborations with pharmaceutical companies. The company has entered into significant partnerships, such as its collaboration with GlaxoSmithKline for the development of COVID-19 treatments, which can lead to milestone payments and royalties on future sales. Additionally, Vir may receive funding from government grants and contracts, especially during public health emergencies, contributing to its financial earnings.

Vir Biotechnology Financial Statement Overview

Summary

Vir Biotechnology is facing significant financial challenges, with negative net profit margins, declining revenue growth, and ongoing cash flow issues. The balance sheet shows low leverage but negative returns on equity, indicating financial instability.

Income Statement

Vir Biotechnology's income statement shows significant challenges with negative net profit margins and declining revenue growth. The TTM data reveals a gross profit margin of 95.53%, but this is overshadowed by a net loss, indicating inefficiencies in cost management. The revenue growth rate is negative, reflecting a downturn in sales performance. Overall, the company is struggling to maintain profitability.

Balance Sheet

The balance sheet indicates a relatively low debt-to-equity ratio of 0.10, suggesting conservative leverage. However, the return on equity is negative, highlighting the company's inability to generate positive returns for shareholders. The equity ratio is stable, but the overall financial health is compromised by persistent losses.

Cash Flow

The cash flow statement shows negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings, but overall cash flow management remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.86M	74.20M	86.18M	1.62B	1.10B	67.25M
Gross Profit	-438.52M	-404.44M	-486.65M	994.83M	581.54M	67.25M
EBITDA	-511.54M	-508.91M	-641.64M	839.85M	426.56M	-291.54M
Net Income	-499.65M	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.02B	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	506.51M	905.35M	1.52B	2.40B	708.14M	736.86M
Total Debt	100.17M	97.89M	124.54M	127.97M	137.49M	70.18M
Total Liabilities	223.35M	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	796.10M	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-460.43M	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-453.54M	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	364.46M	499.37M	164.73M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	4.01M	4.39M	7.38M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 6.39 is above the 20-day moving average (MA) of 5.64, above the 50-day MA of 5.71, and above the 200-day MA of 5.80, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 63.61 is Neutral, neither overbought nor oversold. The STOCH value of 83.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$344.88M	―	-43.11%	―	―	-5.71%
SEPN	59 Neutral	$1.32B	―	-22.38%	―	2147.20%	-269.99%
XNCR	57 Neutral	$1.02B	-7.88	-19.61%	―	38.16%	48.43%
IOVA	53 Neutral	$913.03M	―	-53.89%	―	175.62%	19.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIR	51 Neutral	$889.01M	―	-49.06%	―	-78.55%	7.74%
IVA	44 Neutral	$616.04M	-0.99	―	―	-12.52%	-82.84%

Vir Biotechnology Corporate Events

Vir Biotechnology’s Earnings Call: Achievements and Challenges

Vir Biotechnology, Inc.’s recent earnings call presented a balanced sentiment, reflecting both significant achievements and ongoing challenges. The company highlighted substantial progress in its key clinical programs and a robust financial position, setting a clear path for future value creation. However, continuous financial losses and high research and development (R&D) expenses remain as notable challenges.

Vir Biotechnology Reports Q3 2025 Financial Results and Clinical Progress

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for serious infectious diseases and cancer, leveraging its expertise in the immune system and innovative technologies like the PRO-XTEN masking platform.

Vir Biotechnology’s Innovative HDV Study: A Potential Game-Changer in Viral Treatment

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 2b study titled ‘A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)’. The study aims to assess the efficacy and safety of a new combination therapy for chronic Hepatitis D Virus (HDV) infection, a significant health concern due to its severe liver complications.

Vir Biotechnology’s Promising Phase 3 Study for Chronic HDV Treatment

Vir Biotechnology, Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)’. The study aims to assess the effectiveness and safety of a combination therapy for patients with chronic hepatitis D virus (HDV) infection who have not responded to bulevirtide treatment.

Vir Biotechnology’s Phase 3 Study on HDV Treatment: A Potential Game-Changer?

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 3 study titled A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1). The study aims to assess the effectiveness and safety of the combination therapy for treating chronic hepatitis delta, a significant health concern due to its severe liver complications.

Vir Biotechnology’s Innovative Approach in HER2-Expressing Cancer Treatment: A Study Update

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 1 clinical study titled A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. The study aims to assess the safety, pharmacokinetics, and preliminary activity of VIR-5818, both alone and combined with pembrolizumab, in treating HER2+ tumors. This research is significant as it explores new treatment avenues for challenging cancer types.

Vir Biotechnology’s Promising Prostate Cancer Study: A Potential Game-Changer?

Vir Biotechnology, Inc. is conducting a Phase 1 study titled A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer. The study aims to evaluate the safety and efficacy of VIR-5500 in treating hormone-refractory prostate cancer, a significant step in addressing this challenging condition.

Vir Biotechnology’s Phase 1 Study on VIR-5525: A Potential Game-Changer in Cancer Treatment?

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors.’ The study aims to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5525, both as a standalone treatment and in combination with pembrolizumab, for patients with EGFR-positive solid tumors.

Vir Biotechnology’s Hepatic Impairment Study: A Potential Game Changer?

Vir Biotechnology, Inc. is conducting a Phase 1 study titled Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434. The study aims to evaluate the pharmacokinetics, safety, and tolerability of VIR-2218 and VIR-3434, both as monotherapies and in combination, in adults with varying degrees of hepatic impairment, including cirrhosis. This research is significant as it seeks to understand how these drugs behave in patients with liver conditions, potentially informing future treatments.